No Data
No Data
Pfizer Sticks to 2025 Profit View as It Shrugs off Plunging Paxlovid Sales for COVID
Pfizer Reports Strong Q1 2025 Results and Reaffirms Guidance
Is it all Trump's fault for wildly swinging the 'tariff club'? Pfizer: Uncertainty has hindered manufacturing and research and development investment.
① Pfizer CEO Albert Bourla stated that the uncertainty surrounding Trump's proposed pharmaceutical tariffs is hindering the company's manufacturing and R&D investments in the USA; ② Bourla emphasized that the company hopes to see "certainty," meaning clear tariffs or additional incentives, to increase investment in the USA.
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
Pfizer's Earnings Call: Growth Amidst Challenges
UBS Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $24